Live
- Sambhal stone-pelting accused will face strict action, says BJP
- Man smashes Ola scooter after receiving Rs 90,000 bill for repairs
- Ajit Pawar elected as leader of NCP in Maha Assembly
- Love, murder, cover-up: Married man kills live-in partner, sets body on fire
- Kishida launches new group within ruling LDP: Report
- Shreya Ghoshal to perform in 'Tripura Tourism Promo Fest'
- Congress lost its stature as brand, now just a regional party: Kangana
- Abu Dhabi T10: New York Strikers reflect on dominant bowling display in win over Bangla Tigers
- VHP Karnataka Resolves to Oppose Alleged Land Encroachments Under Wakf Board
- Formula 1: Verstappen claims fourth drivers' title as Russell leads Mercedes 1-2 in Las Vegas
New patch for diabetics may make painful jabs history
While syringes, pens, pumps and jet injectors have given diabetics options for their insulin delivery for many years now, a new device called OneTouch Via could change the game.
Washington D.C: While syringes, pens, pumps and jet injectors have given diabetics options for their insulin delivery for many years now, a new device called OneTouch Via could change the game.
People with type 1 and type 2 diabetes who used the new OneTouch Via mealtime, on-demand insulin delivery system reported they missed fewer doses and felt less stress about dosing compared to multiple daily injections, according to research presented by Calibra Medical, Inc., one of the Johnson & Johnson Diabetes Care Companies, at the annual American Diabetes Association (ADA) conference.
Results of the Market Acceptance Evaluation (MAE) study also demonstrated that physicians were more likely to recommend the innovative insulin delivery device to patients who are not at A1C goals or who are new to rapid-acting insulin (RAI) therapy.
The new OneTouch Via is a wearable, on-demand insulin delivery system in development that allows patients to discreetly deliver rapid-acting, or bolus, insulin at mealtimes by simply pressing two buttons on the device, accessible even through clothing. The thin, water-resistant patch can be worn continuously for up to three days, providing injection-free delivery of insulin when needed.
"People with diabetes can often feel embarrassment or discomfort when they need to inject insulin at mealtimes or when snacking. In a social situation, they may choose to miss a dose so they don't have to take themselves out of the moment, but avoiding needed insulin doses may lead to serious health complications over time," said Dr. Brian Levy.
Levy added, "Because patients in the study were empowered to dose discreetly with the OneTouch Via, they felt encouraged to dose more often - and ultimately, they reported missing fewer doses and better adherence to their treatment regimen."
The healthcare professionals who assisted with the study noted that they preferred the OneTouch Via over both insulin pens and syringes (75 percent and 100 percent, respectively) and would be likely to recommend it to their patients. The doctors also reported that they would start patients on mealtime insulin earlier because of the ease of use of the OneTouch Via patch.
The study appears in American Diabetes Association (ADA) Conference.
